ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases

Inclusion Criteria: * confirmed diagnosis of inherited metabolic diseases; including the following: * Hurler Syndrome (MPS I) * Hurler-Scheie Syndrome * Hunter Syndrome (MPS II) * Sanfilippo Syndrome A and B(MPS III) * Maroteaux-Lamy Syndrome (MPS VI) * Krabbe Disease (Globoid Leukodystrophy) * Metachromatic Leukodystrophy (MLD) * Adrenoleukodystrophy (ALD and AMN) * Sandhoff Disease * Tay Sachs Disease * Pelizaeus Merzbacher (PMD) * Niemann-Pick Disease * Alpha-mannosidosis * I-Cell Disease (ML II) * Fucosidosis * GM I Gangliosidosis * Canavan Disease * must be \<16 years of age at the time of study enrollment * must have a good performance status (Lansky ≥80%) * must have adequate function of other organ systems including: kidney, liver, heart and lungs * must have given valid written informed consent * must have a minimum life expectancy of at least 6 months * must be determined to be a good candidate for a standard umbilical cord blood transplant * must have an IQ \>70 or if too young for IQ testing the potential to reach this endpoint by age 5 Exclusion Criteria: * HIV, Hepatitis B and/or Hepatitis C positive * concurrently involved in any other clinical study that affects engraftment or immune reconstitution * uncontrolled seizures, apnea, evidence of aspiration pneumonia, or evidence of brain stem involvement * uncontrolled infections * prior allogeneic stem cell transplant with cytoreduction preparative therapy within 12 months of…